Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22601293 | 1.00 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL19818246 | 1.00 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL13312942 | 1.00 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL280337 | 1.00 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL680648 | 1.00 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL7752845 | 1.00 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL3047337 | 1.00 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL16202652 | 1.00 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL4843434 | 0.97 | TRPA1 (0.50) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL3914000 | 0.97 | TRPA1 (0.50) | TRPA1TRPM8CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976061-B2 | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | Merck Sharp & Dohme, LLC (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230183242-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-15 | — | — | US | disclosed |
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-16 | — | — | US | disclosed |
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-03 | — | — | US | disclosed |
| US-10815223-B2 | Process for producing Lamivudine and Emtricitabine | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2020-10-27 | — | — | US | disclosed |
| EP-3440077-B1 | PROCESS FOR PRODUCING LAMIVUDINE AND EMTRICITABINE | UNIV NELSON MANDELA METROPOLITAN (ZA) | 2020-07-01 | — | — | EP | disclosed |
| US-20190330239-A1 | INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME CORP. (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190211004-A1 | PROCESS FOR PRODUCING LAMIVUDINE AND EMTRICITABINE | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2019-07-11 | — | — | US | disclosed |
| US-20170283424-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170283424-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-8999998-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140323418-A1 | SELECTIVE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20130172187-A1 | USE OF ARYL CARBAMATES IN AGRICULTURE AND OTHER PLANT-RELATED AREAS | NORTH CAROLINA STATE UNIVERSITY | 2013-07-04 | — | — | US | disclosed |
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2012006276-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH ARYL CARBAMATES | NORTH CAROLINA STATE UNIVERSITY (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172187-A1 | USE OF ARYL CARBAMATES IN AGRICULTURE AND OTHER PLANT-RELATED AREAS | CTRC, ACE, DDT | TRPA1 566/4885TRPM8 1808/4885CA1 1810/4885 |
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | TRPA1 3391/4885TRPM8 4099/4885CA1 3760/4885 |
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | TRPA1 838/4885TRPM8 1555/4885CA1 4848/4885 |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | TRPA1 35/4885TRPM8 111/4885CA1 2651/4885 |
| US-20230183242-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | TYK2, JAK3, IFNAR1 | TRPA1 3562/4885TRPM8 2894/4885CA1 4704/4885 |
| US-20140323418-A1 | SELECTIVE KINASE INHIBITORS | SYK, BTK, LCK | TRPA1 4412/4885TRPM8 3944/4885CA1 4725/4885 |
| US-20190330239-A1 | INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | DGAT2, DGAT1, MOGAT2 | TRPA1 3257/4885TRPM8 4042/4885CA1 4477/4885 |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | CSF1R, CSF3R, MSR1 | TRPA1 4028/4885TRPM8 3764/4885CA1 241/4885 |
| US-20190211004-A1 | PROCESS FOR PRODUCING LAMIVUDINE AND EMTRICITABINE | TYMS, TYMP, DCTD | TRPA1 4871/4885TRPM8 4835/4885CA1 4316/4885 |
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | EGFR, ERBB2, ERBB3 | TRPA1 838/4885TRPM8 1551/4885CA1 4852/4885 |
| US-20170283424-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | TRPA1 3391/4885TRPM8 4099/4885CA1 3760/4885 |
| US-11976061-B2 | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | TRPA1 3808/4885TRPM8 4654/4885CA1 4229/4885 |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | CSF1R, CSF3R, FLT3 | TRPA1 3347/4885TRPM8 3925/4885CA1 279/4885 |
| US-10815223-B2 | Process for producing Lamivudine and Emtricitabine | TYMS, TYMP, DCTD | TRPA1 4871/4885TRPM8 4835/4885CA1 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.